We are live on ! Find out more
DOVA

Dova Pharmaceuticals, Inc. Common Stock
DOVA

Delisted

DOVA was delisted on the 11th of November, 2019.

Back to rankings

0 hedge funds and large institutions have $0 invested in Dova Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 72 → 0 (-72)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $278M → $0 (-$278M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 72

Holders
–
Holders Change
-72
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
72
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$104M
2
AAM
Alpine Associates Management
Florida
-$39.7M
3
BlackRock
BlackRock
New York
-$27.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$16.6M
5
GKIM
GW&K Investment Management
Massachusetts
-$9.24M
Name Holding Trade Value Shares
Change 		Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
– -$1.33M -47,674 Closed
AllianceBernstein
27
AllianceBernstein
Tennessee
– -$1.21M -43,400 Closed
YCM
28
Yakira Capital Management
Connecticut
– -$1.12M -40,000 Closed
Bank of New York Mellon
29
Bank of New York Mellon
New York
– -$1.06M -38,065 Closed
N
30
Nuveen
North Carolina
– -$971K -34,720 Closed
GCIA
31
Gabelli & Co Investment Advisers
New York
– -$922K -33,000 Closed
Bank of America
32
Bank of America
North Carolina
– -$894K -31,971 Closed
Deutsche Bank
33
Deutsche Bank
Germany
– -$800K -28,662 Closed
SC
34
Sculptor Capital
New York
– -$679K -24,300 Closed
Fidelity Investments
35
Fidelity Investments
Massachusetts
– -$635K -22,701 Closed
Walleye Trading
36
Walleye Trading
New York
– -$624K -22,311 Closed
SEI Investments
37
SEI Investments
Pennsylvania
– -$586K -20,956 Closed
VF
38
Virtu Financial
New York
– -$523K -18,729 Closed
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
– -$456K -16,300 Closed
CLOS
40
Compagnie Lombard Odier SCmA
Switzerland
– -$392K -14,000 Closed
Barclays
41
Barclays
United Kingdom
– -$381K -13,638 Closed
Simplex Trading
42
Simplex Trading
Illinois
– -$364K -13,030 Closed
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
– -$359K -12,827 Closed
Bank of Montreal
44
Bank of Montreal
Ontario, Canada
– -$355K -12,731 Closed
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
– -$351K -12,570 Closed
Citigroup
46
Citigroup
New York
– -$350K -12,532 Closed
Federated Hermes
47
Federated Hermes
Pennsylvania
– -$256K -9,146 Closed
ProShare Advisors
48
ProShare Advisors
Maryland
– -$244K -8,744 Closed
BCM
49
BlueCrest Capital Management
Jersey
– -$238K -8,500 Closed
HF
50
HRT Financial
New York
– -$228K -8,175 Closed
1
2
3

DOVA Hedge Fund Activity: Q4 2019 in Review

0 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q4 2019, worth a combined $0 — down 100% from $278M a quarter earlier.

Sellers outnumbered buyers: 72 funds closed out of DOVA and 0 opened new positions — a net loss of 72 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Perceptive Advisors, exiting entirely with an estimated $104M sold.

  • 0 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q4 2019, down from 72 in Q3 2019.
  • Funds reported $0 of Dova Pharmaceuticals, Inc. Common Stock stock for Q4 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 72 closed out, a net change of -72 holders.
  • The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Perceptive Advisors, an estimated $104M sold.

Based on aggregated 13F filings for Q4 2019.